NKT Thera Closes $8M VC Round to Develop Rxs Based on NK Cell IP from Boston Institutions

NKT licensed the IP from Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital. As a result, each of the Harvard Med-affiliated institutes has been awarded an undisclosed equity stake in the company.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories